semaglutide clinical trials and Cardiovascular Outcomes in Obesity without Diabetes Frontiers | Semaglutide in cognitive

Results also show that more than 4 in 5 (81%) of patients were prescribed a low maintenance dose of their GLP-1 drug, and that made a difference as well

Common side effects observed in Phase 2 trials include nausea, vomiting, diarrhoea, and injection site reactions, particularly during dose escalation

Further investigation into the possible effect of GLP-1-mediated effects on adipocyte glycogen synthesis may be beneficial in better understanding the role of GLP-1 in mediating adipocyte increases in energy metabolism

Lilly has announced promising data from its NCT 04881760 phase 2 study of retatrutide, a potential obesity drug